- CRS Publications
- News
News
Authors:
Date:
Business Wire: June 29, 2016 – CAMBRIDGE, MA, U.S.A. – Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will unveil preclinical data showing the promise of its proprietary GalXC™ subcutaneous (SC) delivery platform as…
Authors:
Date:
Business Wire: June 9, 2016 – ARDSLEY, NY, U.S.A. – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced pharmacokinetic (PK) data from a phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal…
Authors:
Date:
Business Wire: June 6, 2016 – TORONTO, Canada – Highland Therapeutics Inc.’s wholly owned subsidiary, Ironshore Pharmaceuticals and Development, Inc. (“Ironshore”), today announced positive clinical data from the second phase 3 pivotal trial of its investigational drug product, HLD-200 (delayed-…
Authors:
Date:
Business Wire: May 26, 2016 – DUBLIN, OH, U.S.A. – Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced the receipt of an initial notice of award for a fast-track Small Business Innovation Research (SBIR) grant providing for up to $1.8 million from the National Institutes of Health’s (NIH’s…
Authors:
Date:
Business Wire: May 16, 2016 – STOCKHOLM, Sweden – Nanologica entered into a license and collaboration agreement with Alcyone Lifesciences to develop Abela, a treatment for motor neuron disorders including ALS.
Nanologica today announced that it has entered into a License and Collaboration…
Authors:
Date:
Business Wire: May 12, 2016 – PARIS, France, and STANS, Switzerland – NLS Pharma Group announced the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a phase IIb clinical trial with its lead compound Mazindol. The study is…
